AZN vs. TECH: AstraZeneca vs. Bio-Techne Stock Comparison

November 11, 2026

How do AstraZeneca (AZN) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AstraZeneca (AZN) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while TECH is classified in Life Sciences Tools & Services.

Bio-Techne (TECH) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for AstraZeneca (AZN) and Bio-Techne (TECH)
Profile Item	AZN	TECH
Name	AstraZeneca PLC American Depositary Shares	Bio-Techne Corp.
Country/Region	United Kingdom	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Life Sciences Tools & Services
GICS Sub-Industry	Pharmaceuticals	Life Sciences Tools & Services
Market Capitalization	289.14 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	May 12, 1993	February 9, 1989
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

AZN

TECH

GSPC

AstraZeneca (AZN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AstraZeneca (AZN) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AstraZeneca (AZN) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Total Return (1Y)	12.64%	27.56%
Total Return (3Y, Annualized)	15.75%	9.11%
Total Return (5Y, Annualized)	10.63%	-9.91%

Risk Profile

Drawdown History

AZN

TECH

GSPC

AstraZeneca (AZN) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AstraZeneca (AZN) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Volatility (1Y, Annualized)	28.21%	43.08%
Beta (5Y)	0.22	1.26
Max Drawdown (5Y)	-27.87%	-65.87%
Avg. Volume (3M)	3.14M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

AZN and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Sharpe Ratio (1Y)	0.30	0.54
Sortino Ratio (1Y)	0.44	0.82

Profitability

ROE (TTM)

Both AstraZeneca (AZN) at 22.57% and Bio-Techne (TECH) at 8.33% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.57%

Max: 109.18%
AZN: 22.57%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

For every dollar of sales, both AstraZeneca (AZN) at 17.68% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.68%

Max: 18.05%
AZN: 17.68%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

AstraZeneca (AZN) at 29.57% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.57%

Max: 83.12%
AZN: 29.57%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
ROE (TTM)	22.57%	8.33%
ROA (TTM)	8.59%	6.38%
Net Margin (TTM)	17.68%	14.00%
Operating Margin (TTM)	29.57%	12.21%
Gross Margin (TTM)	81.78%	66.23%

Growth

Revenue Growth

Both AstraZeneca (AZN) at 8.63% and Bio-Techne (TECH) at -0.38% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while AstraZeneca (AZN) at 45.33% is closer to the peer norm — faster per-share earnings growth for TECH.

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Revenue Growth (YoY)	8.63%	-0.38%
Revenue Growth (3Y CAGR)	9.82%	2.25%
EPS Growth (YoY)	45.33%	152.17%
EPS Growth (3Y CAGR)	45.80%	-12.97%

Financial Strength

Current Ratio (MRQ)

Both AstraZeneca (AZN) at 1.01 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.01

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
AZN: 1.01
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Techne (TECH) at 0.13 carries an industry-typical debt-to-equity mix, while AstraZeneca (AZN) at 0.66 uses more debt funding than most peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.66

Max: 1.42
AZN: 0.66
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Current Ratio (MRQ)	1.01	2.28
Debt / Equity (MRQ)	0.66	0.13
Net Debt / EBITDA	1.23	-0.20

Dividends

Dividend Yield (TTM)

Both AstraZeneca (AZN) at 1.73% and Bio-Techne (TECH) at 0.44% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73%

AZN: 1.73%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both AstraZeneca (AZN) at 45.38% and Bio-Techne (TECH) at 27.59% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

45.38%

AZN: 45.38%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
Dividend Yield (TTM)	1.73%	0.44%
Dividend Payout Ratio (TTM)	45.38%	27.59%

Valuation

P/E Ratio (TTM)

AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.37

Max: 85.34
Q3: 43.46
Median: 26.69
AZN: 26.37
Q1: 13.30
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AstraZeneca (AZN) at 4.63 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.63

Max: 58.18
Q3: 25.77
Median: 7.30
AZN: 4.63
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both AstraZeneca (AZN) at 5.59 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

AZN

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.59

Max: 13.53
Q3: 6.54
AZN: 5.59
Median: 3.25
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

AstraZeneca (AZN) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AstraZeneca (AZN) and Bio-Techne (TECH)
Metric	AZN	TECH
P/E Ratio (TTM)	26.37	62.74
P/S Ratio (TTM)	4.63	9.31
P/B Ratio (MRQ)	5.59	5.28
Free Cash Flow Yield (TTM)	1.95%	2.39%